Novavax Inc (NVAX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$6.58
Buy
$6.61
$-0.12 (-1.79%)
Prices updated at 13 Dec 2025, 00:59 EST
| Prices minimum 15 mins delay
Prices in USD
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 70.28 |
| 2023 | 38.21 |
| 2022 | 43.55 |
| 2021 | 100.00 |
| 2020 | 100.00 |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 1.03 |
| 2024 | 1.36 |
| 2023 | 0.73 |
| 2022 | 0.43 |
| 2021 | 8.55 |
| 2020 | 26.22 |
| 2019 | 5.45 |
| 2018 | 16.84 |
| 2017 | 13.34 |
| 2016 | 21.56 |
| 2015 | 57.51 |
Price/Forward earnings (YTD)
-6.99
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -11.17 |
| 2023 | -26.88 |
| 2022 | -27.21 |
| 2021 | -83.85 |
| 2020 | -47.65 |
| 2019 | -69.67 |
| 2018 | -72.38 |
| 2017 | -52.75 |
| 2016 | -71.75 |
| 2015 | -47.41 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | 2.52 |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | 1.32 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
